Evidence-based approaches improve glycaemic control in patients with advanced cancer, highlighting the importance of balancing treatment and quality of life.
Patients with advanced cancer often have type 2 diabetes mellitus (T2DM) and are on multiple medications that affect glycaemic control. Patients can have pre‑existing diabetes or treatment- and glucocorticoid-induced hyperglycaemia. Optimal management of glycaemic control differs at varying stages of life and depends on overall goals of care. This article summarises the evidence-based management of T2DM in patients with advanced cancer, including management of glucocorticoid-induced hyperglycaemia, and appropriate targets for glycated haemoglobin (HbA1c). T2DM often co-exists in patients with advanced cancer. Management is aimed at reducing the complications of hyperglycaemia and hypoglycaemia, and maximising quality of life. Interventions and treatments need to be balanced against quality of life and prognosis.
No takes yet. Share an insight, caveat, or question.
Weerasinghe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: